Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Issues Medicare Part B Competitive Acquisition Proposed Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposed rule seeks comments on which drugs should be included in the competitive acquisition program, which will start in 2006. CMS is also asking for input related to the bidding process for vendors, including how many should be selected.

You may also be interested in...



Medicare Part B Competitive Acquisition Program Gets Wide Implementation

Under CMS’ interim final rule, the Part B competitive acquisition program taking effect in 2006 will cover 181 drugs as a single category and use a single national distribution area.

Medicare Part B Competitive Acquisition Program Gets Wide Implementation

Under CMS’ interim final rule, the Part B competitive acquisition program taking effect in 2006 will cover 181 drugs as a single category and use a single national distribution area.

CMS Physician Panel Will Discuss Part B Drug Competitive Bidding March 7

Practicing Physicians Advisory Council will provide stakeholder input to the Centers for Medicare & Medicaid Services on its competitive bidding proposed rule. Medicare Rx physician education efforts are also on the group’s agenda.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel